SXTP — 60 Degrees Pharmaceuticals Share Price
Last trade - 00:00- $4.35m
- $10.60m
- $0.68m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 6.38 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -236.83% | ||
| Return on Equity | n/a | ||
| Operating Margin | -1425.84% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 2.18 | 6.35 | 0.51 | 0.25 | 0.68 | 1.31 | 2.36 | -25.24% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. It is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The Company's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is an antimalarial indicated for the prophylaxis of malaria in patients aged 18 years of age and older. It is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- June 1st, 2022
- Public Since
- July 12th, 2023
- No. of Shareholders
- 21
- No. of Employees
- 3
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 1,472,891
- Address
- 1025 Connecticut Avenue Nw, Suite 1000, WASHINGTON, 20036
- Web
- https://60degreespharma.com/
- Phone
- +1 2023275422
- Contact
- Patrick Gaynes
- Auditors
- RBSM LLP
Similar to SXTP
Agriforce Growing Systems
NASDAQ Capital Market
Akari Therapeutics
NASDAQ Capital Market
Akebia Therapeutics
NASDAQ Capital Market
ASP Isotopes
NASDAQ Capital Market
Assertio Holdings
NASDAQ Capital Market
FAQ
As of Today at 19:00 UTC, shares in 60 Degrees Pharmaceuticals are trading at $2.95. This share price information is delayed by 15 minutes.
Shares in 60 Degrees Pharmaceuticals last closed at $2.95 and the price had moved by -78.95% over the past 365 days. In terms of relative price strength the 60 Degrees Pharmaceuticals share price has underperformed the S&P500 Index by -80.57% over the past year.
The overall consensus recommendation for 60 Degrees Pharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out more60 Degrees Pharmaceuticals does not currently pay a dividend.
60 Degrees Pharmaceuticals does not currently pay a dividend.
60 Degrees Pharmaceuticals does not currently pay a dividend.
To buy shares in 60 Degrees Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $2.95, shares in 60 Degrees Pharmaceuticals had a market capitalisation of $4.35m.
Here are the trading details for 60 Degrees Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: SXTP
Based on an overall assessment of its quality, value and momentum 60 Degrees Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in 60 Degrees Pharmaceuticals is $5.80. That is 96.61% above the last closing price of $2.95.
Analysts covering 60 Degrees Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$3.74 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like 60 Degrees Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -23.42%.
As of the last closing price of $2.95, shares in 60 Degrees Pharmaceuticals were trading -45.92% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The 60 Degrees Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on 60 Degrees Pharmaceuticals' directors